Platinum chemotherapy after tarlatamab for small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a standard chemotherapy combination (carboplatin and etoposide) again can help people with small cell lung cancer whose disease has progressed while on the drug tarlatamab. It aims to see if this approach can control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have small cell lung cancer that has spread or is advanced and is not curable with standard treatments.
- Your cancer has grown or come back after at least 90 days since your last platinum-based chemotherapy (like carboplatin or cisplatin).
- You have received only one prior line of chemotherapy for extensive-stage disease.
- You are currently on or recently took tarlatamab and your cancer has progressed while on it.
- You are willing to have a new biopsy of your tumor after progression on tarlatamab (or have an archived sample from after progression).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Extensive Disease Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.